SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

Through the leveraging of remote participation, plasma NGS offers an optimal mechanism for characterizing resistance to emerging targeted therapies in rare cancer populations, though sensitivity depends on adequate tumor DNA samples. Repeat cfDNA analysis on therapy may offer an objective monitoring approach to remotely study treatment response. READ ARTICLE

Journal of Thoracic Oncology DOI: 10.1016/j.jtocrr.2021.100151

Authors: Marissa N. Lawrence, Rubii M. Tamen, Pablo Martinez, Alicia Sable-Hunt, Tony Addario, Pete Barbour, Tristan Shaffer, Seyed Ali Hosseini, Caterina Bertucci, Lee P. Lim, Fangxin Hong, Kesi Michael, George R. Simon, Jonathan W. Riess, Mark M. Awad, Geoffrey R. Oxnard

Real-World OutcomesKirk SmithFebruary 1, 2021ALK, Drug resistance, Plasma NGS, Remote participation